1
|
Holub K, Passeri T, Loap P, Noorelahi M, Beddok A, Feuvret L, Helfre S, Guichard JP, Goudjil F, Pasquie I, Dendale R, Froelich S, Calugaru V, Mammar H. Efficacy of Protontherapy in Atypical Meningiomas. Int J Radiat Oncol Biol Phys 2023; 117:e134-e135. [PMID: 37784698 DOI: 10.1016/j.ijrobp.2023.06.938] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) To assess the efficacy and safety of complementary radiotherapy (RT) [by proton beams alone (PT) or in combination with photon beams (Ph)] to surgery in the local treatment of atypical meningiomas. MATERIALS/METHODS One hundred one consecutive patients with atypical (WHO grade II) meningiomas were treated with PT +/- Ph at our institution between Nov 1996 to Sep 2022. The total median dose was 59.4 Gy RBE (range 59.4- 68.4) with Proton component alone (n = 76) or PT + Ph (n = 25). The median age at RT was 57.2 years old (range 22.0-79.6). Localization was supratentorial in 62 patients (61.4%), skull base in 29 patients (28.7%), and infratentorial in 10 patients (9.9%). Gross tumor resection was reported in 20 cases (19.8%) and subtotal in 81 (80.2%), 34 patients underwent multiples (2-4) surgeries before RT. Overall survival (OS), meningioma related survival (MRS), Progression Free Survival (PFS), Time to Local progression (TLP), and 3, 5 and 10-year survival rates were evaluated using Kaplan-Meier method. All post-PT clinical toxicity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE v 5.0). RESULTS During follow-up after PT (median 47.8 months), local progression was reported in 26 patients (25.7%) and 24 patients died (including 13 meningioma-related deaths). Median TLP was 34.3 months (IC 95% 1.9-128.1), OS was 163 months (IC95% 93.9-232.2), MRS was 34.3 (IC 95% 1.9-128.1) and PFS was 41.4 (IC 95% 1.5-217.8). Actuarial 3, 5 and 9-year OS was 83%, 78% and 66%, while MRS was 89%, 83% and 71% respectively. Patients treated with PT alone presented better OS with 9 deaths (6 meningioma-related deaths) and median of 163.0 months [IC95% (93.9-232.2)], 3y-95%, 5y-93%, 10y-65%, respectively. However, the Patients treated with PT+Ph presented 15 deaths (7 meningioma-related deaths) and median of 51.9 months [IC 95% (7.0-96.8); 2y-75%, 5y-50%, 10y-50%) (p = 0.018). Median TLR was 36.4 months (26.6-46.2) after PT alone and 11.9 months (10.3-13.5) after PT+Ph. However, well-controlled radionecrosis ≤ Grade2 was more frequent after PT alone 20 cases vs 3 cases after PT+Ph. Long-term symptoms was observed during the last visit in 45 patients (44.6%) treated with PT vs. 8 (38.1%) treated with PT+Ph. CONCLUSION PT alone or PT+Ph were effective and well-tolerated treatment in WHO grade II meningioma and PT alone appeared to be better for the local control and survival.
Collapse
Affiliation(s)
- K Holub
- Department of Radiation Oncology-Institut Curie, Paris, France; University of Barcelona, Barcelona, Spain
| | - T Passeri
- Lariboisière Hospital Paris - France, Paris, France
| | - P Loap
- Department of Radiation Oncology-Institut Curie, Paris, France
| | - M Noorelahi
- Department of Radiation Oncology-Institut Curie, Paris, France
| | - A Beddok
- Department of Radiation Oncology-Institut Curie, Paris, France
| | - L Feuvret
- Department of Radiation Oncology-Institut Curie, Paris, France
| | - S Helfre
- Department of Radiation Oncology-Institut Curie, Paris, France
| | - J P Guichard
- Lariboisière Hospital Paris - France, Paris, France
| | - F Goudjil
- Department of Radiation Oncology-Institut Curie, Paris, France
| | - I Pasquie
- Department of Radiation Oncology-Institut Curie, Paris, France
| | - R Dendale
- Department of Radiation Oncology-Institut Curie, Paris, France
| | - S Froelich
- Lariboisière Hospital Paris - France, Paris, France
| | - V Calugaru
- Department of Radiation Oncology-Institut Curie, Paris, France
| | - H Mammar
- Department of Radiation Oncology-Institut Curie, Paris, France
| |
Collapse
|
2
|
Leite AMM, Bonfrate A, Da Fonseca A, Lansonneur P, Alapetite C, Mammar H, De Marzi L. Double scattering and pencil beam scanning Monte Carlo workflows for proton therapy retrospective studies on radiation-induced toxicities. Cancer Radiother 2023:S1278-3218(23)00070-7. [PMID: 37164897 DOI: 10.1016/j.canrad.2023.02.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Revised: 02/02/2023] [Accepted: 02/07/2023] [Indexed: 05/12/2023]
Abstract
PURPOSE Monte Carlo (MC) simulations can be used to accurately simulate dose and linear energy transfers (LET) distributions, thereby allowing for the calculation of the relative biological effectiveness (RBE) of protons. We present hereby the validation and implementation of a workflow for the Monte Carlo modelling of the double scattered and pencil beam scanning proton beamlines at our institution. METHODS The TOPAS/Geant4 MC model of the clinical nozzle has been comprehensively validated against measurements. The validation also included a comparison between simulated clinical treatment plans for four representative patients and the clinical treatment planning system (TPS). Moreover, an in-house tool implemented in Python was tested to assess the variable RBE-weighted dose in proton plans, which was illustrated for a patient case with a developing radiation-induced toxicity. RESULTS The simulated range and modulation width closely matches the measurements. Gamma-indexes (3%/3mm 3D), which compare the TPS and MC computations, showed a passing rate superior to 98%. The calculated RBE-weighted dose presented a slight increase at the necrosis location, within the PTV margins. This indicates the need for reporting on the physical and biological effects of irradiation in high dose regions, especially at the healthy tissues and increased LET distributions location. CONCLUSION The results demonstrate that the Monte Carlo method can be used to independently validate a TPS calculation, and to estimate LET distributions. The features of the in-house tool can be used to correlate LET and RBE-weighted dose distributions with the incidence of radiation-induced toxicities following proton therapy treatments.
Collapse
Affiliation(s)
- A M M Leite
- Inserm U 1021- CNRS UMR 3347, Institut Curie, PSL Research University, University Paris Saclay, 91898, Orsay, France; Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, centre universitaire, 91898 Orsay, France
| | - A Bonfrate
- Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, centre universitaire, 91898 Orsay, France
| | - A Da Fonseca
- Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, centre universitaire, 91898 Orsay, France
| | - P Lansonneur
- Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, centre universitaire, 91898 Orsay, France
| | - C Alapetite
- Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, centre universitaire, 91898 Orsay, France
| | - H Mammar
- Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, centre universitaire, 91898 Orsay, France
| | - L De Marzi
- Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, centre universitaire, 91898 Orsay, France; Inserm LITO, Institut Curie, PSL Research University, University Paris Saclay, 91898 Orsay, France.
| |
Collapse
|
3
|
Holub K, Froelich S, Guichard J, Passeri T, Polivka M, Carpentier A, Adle-Biassette H, Feuvret L, Lot G, Bolle S, Beddok A, El Ayachy R, Goudji F, Pasquie I, Calugaru V, Dendale R, Mammar H. PO-1129 Post-operative Proton Beam Therapy in cervical chordoma. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03093-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
4
|
Scher N, Bentahila R, Alapetite C, Beddok A, Helfre S, Bolle S, Mammar H, Dendale R, Calugaru V, Feuvret L. PH-0170 Proton therapy for adult craniopharyngioma. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07262-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
5
|
Takanen S, Frederic-Moreau T, Otz J, Fawzi M, Aich H, Albert-Dufrois H, Beddock A, Clement-Zhao A, Mammar H, Musat E, Muresan M, Crehange G, Minsat M, Verrelle P, Poortmans P. PO-0859: Postoperative stereotactic brain radiation therapy: a single centre retrospective analysis. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00876-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
6
|
Beddok A, Saint-Martin C, Mammar H, Goudjil F, Zefkili S, Helfre S, Feuvret L, Bolle S, Froelich S, Amessis M, Peurien D, Dendale R, Alapetite C, Calugaru V. PO-0908: Efficacy and Toxicity of Proton therapy and Tomotherapy combination in sacral chordoma patients. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00925-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
7
|
Lansonneur P, Mammar H, Nauraye C, Patriarca A, Hierso E, Dendale R, Prezado Y, De Marzi L. First proton minibeam radiation therapy treatment plan evaluation. Sci Rep 2020; 10:7025. [PMID: 32341427 PMCID: PMC7184593 DOI: 10.1038/s41598-020-63975-9] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2019] [Accepted: 04/08/2020] [Indexed: 11/09/2022] Open
Abstract
Proton minibeam radiation therapy (pMBRT) is a novel dose delivery method based on spatial dose fractionation. pMBRT has been shown to be promising in terms of reduced side effects and superior tumour control in high-grade glioma-bearing rats compared to standard irradiation. These findings, together with the recent optimized implementation of pMBRT in a clinical pencil beam scanning system, have triggered reflection on the possible application to patient treatments. In this context, the present study was designed to conduct a first theoretical investigation of the clinical potential of this technique. For this purpose, a dedicated dose engine was developed and used to evaluate two clinically relevant patient treatment plans (high-grade glioma and meningioma). Treatment plans were compared with standard proton therapy plans assessed by means of a commercial treatment planning system (ECLIPSE-Varian Medical systems) and Monte Carlo simulations. A multislit brass collimator consisting of 0.4 mm wide slits separated by a centre-to-centre distance of 4 or 6 mm was placed between the nozzle and the patient to shape the planar minibeams. For each plan, spread-out Bragg peaks and homogeneous dose distributions (±7% dose variations) can be obtained in target volumes. The Peak-to-Valley Dose Ratios (PVDR) were evaluated between 9.2 and 12.8 at a depth of 20 mm for meningioma and glioma, respectively. Dose volume histograms (DVHs) for target volumes and organs at risk were quantitatively compared, resulting in a slightly better target homogeneity with standard PT than with pMBRT plans, but similar DVHs for deep-seated organs-at-risk and lower average dose for shallow organs. The proposed delivery method evaluated in this work opens the way to an effective treatment for radioresistant tumours and will support the design of future clinical research.
Collapse
Affiliation(s)
- P Lansonneur
- Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, Centre Universitaire, 91898, Orsay, France
| | - H Mammar
- Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, Centre Universitaire, 91898, Orsay, France
| | - C Nauraye
- Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, Centre Universitaire, 91898, Orsay, France
| | - A Patriarca
- Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, Centre Universitaire, 91898, Orsay, France
| | - E Hierso
- Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, Centre Universitaire, 91898, Orsay, France
| | - R Dendale
- Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, Centre Universitaire, 91898, Orsay, France
| | - Y Prezado
- Institut Curie, PSL Research University, University Paris Saclay, Inserm U 1021-CNRS UMR 3347, 91898, Orsay, France
| | - L De Marzi
- Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, Centre Universitaire, 91898, Orsay, France. .,Institut Curie, PSL Research University, University Paris Saclay, Inserm U 1021-CNRS UMR 3347, 91898, Orsay, France.
| |
Collapse
|
8
|
De Marzi L, Nauraye C, Lansonneur P, Pouzoulet F, Patriarca A, Schneider T, Guardiola C, Mammar H, Dendale R, Prezado Y. Spatial fractionation of the dose in proton therapy: Proton minibeam radiation therapy. Cancer Radiother 2019; 23:677-681. [DOI: 10.1016/j.canrad.2019.08.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2019] [Accepted: 08/01/2019] [Indexed: 10/26/2022]
|
9
|
Beddok A, Feuvret L, Noël G, Bolle S, Deberne M, Mammar H, Chaze A, Le Tourneau C, Goudjil F, Zefkili S, Herman P, Dendale R, Calugaru V. Complément de dose de protons pour les cancers du nasopharynx localement évolués : une expérience de l’institut Curie. Cancer Radiother 2019; 23:304-311. [DOI: 10.1016/j.canrad.2019.01.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2018] [Revised: 12/21/2018] [Accepted: 01/16/2019] [Indexed: 12/26/2022]
|
10
|
Mammar H, Polivka M, Belkacemi Y, Lot G, Froelich S, Carpentier A, Clemenceau S, Gaillard S, Paquis P, Birtwisle-Peyrottes I, Burel-Vandenbos F, Mokhtari K, Kerrou K, Talbot J, Dendale R, Bondiau P, Pouyssegur J, Mazure N. Hypoxia and Metabolism Regulation in Chordomas: Correlation Between Biology and Clinical Features for Potential Targeted Therapy. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.774] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
11
|
Feuvret L, Calugaru V, Bolle S, De Marzi L, Nauraye C, Alapetite C, Mammar H, Habrand JL, Dendale R. Irradiation par protons de chondrosarcome de la base du crâne : expérience du centre de protonthérapie d’Orsay. Neurochirurgie 2013. [DOI: 10.1016/j.neuchi.2013.10.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
12
|
Moan G, Gotra D, Joël H, Mammar H. Évaluation de la dose à l’entrée délivrée par le système d’imagerie du cyclotron. Cancer Radiother 2012. [DOI: 10.1016/j.canrad.2012.07.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
13
|
Mammar H, Herault J, Angelier G, Grange J, Caujolle J, Mosci C, Chauvel P. 239 PROTON BEAM THERAPY FOR IRIS MELANOMA: REVIEW FOR 78 CASES. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)70206-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
14
|
Mammar H, Kerrou K, Bondiau P, Angellier G, Thariat J, Benezery K, Heroult J, Leysalle A, Gérard J, Talbot J. Amélioration du contrôle local des chordomes du rachis traités par chirurgie et une irradiation (CyberKnife®) ciblée sur les cellules hypoxiques marquées au 18F-FMiso. Cancer Radiother 2011. [DOI: 10.1016/j.canrad.2011.07.106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
15
|
Bondiau PY, Doyen J, Mammar H, Thariat J, Castelli J, Benezery K, Rucka G. [Reirradiation of spine and lung tumor with CyberKnife]. Cancer Radiother 2010; 14:438-41. [PMID: 20724188 DOI: 10.1016/j.canrad.2010.06.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2010] [Accepted: 06/09/2010] [Indexed: 10/19/2022]
Abstract
We present the results of two retrospective studies, one regarding reirradiation of spinal tumours and the second, concerning lung tumours. In the first case, primary or secondary tumours were located in or in contact with the vertebrae and spinal cord. The first irradiation has given a full dose to the spinal cord. In the second case, primary or secondary lung tumours have already been treated by irradiation alone or by radiochemotherapy. No grade 3 or 4 early toxicity has been found. Preliminary clinical results are encouraging. The use of CyberKnife represents a major therapeutic advance in the management of irradiated spinal or lung lesions. The possibility of sparing organs at risk and increasing the dose in the tumour target volume are the main advantages.
Collapse
Affiliation(s)
- P-Y Bondiau
- Département de Radiothérapie - Cyclotron/CyberKnife, centre Antoine-Lacassagne, 33 avenue de Valombrose, 06189 Nice, France.
| | | | | | | | | | | | | |
Collapse
|
16
|
Mammar H, Kerrou K, Angellier G, Herault J, Tharia J, Benezery K, Rucka G, Gerard J, Talbo J. 18F-FMISO Guided CyberKnife Irradiation, to Overcome Hypoxic Tumor Resistance in Recurrent Cervical Chordoma. Int J Radiat Oncol Biol Phys 2009. [DOI: 10.1016/j.ijrobp.2009.07.1576] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
17
|
Bondiau PY, Beckendorf V, Li G, Castelli J, Thariat J, Benezeri K, Mammar H, Angellier G, Poudenx M. Évaluation de l’apport du Cyberknife® chez le patient âgé. Cancer Radiother 2009. [DOI: 10.1016/j.canrad.2009.08.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
18
|
Pinon F, Caujolle J, Mammar H, Chauvel P, Gastaud P. 278 Analyse rétrospective de 1 000 cas de mélanomes malins de la choroïde et du corps ciliaire reçus depuis l’acquisition en juin 1991 d’un cyclotron pour protonthérapie. J Fr Ophtalmol 2008. [DOI: 10.1016/s0181-5512(08)70875-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
19
|
Feuvret L, Noel G, Habrand J, Pommier P, Alapetite C, Mammar H, Ferrand R, Boisserie G, Beaudre A, Mazeron J. 2385. Int J Radiat Oncol Biol Phys 2006. [DOI: 10.1016/j.ijrobp.2006.07.794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
20
|
Mammar H, Zefkili S, Gaboriaud G, Lambrez R, François P, De Vathaire F, Giraud P. Évaluation des faibles doses et estimations de leurs conséquences lors d'une radiothérapie conformationnelle avec modulation d'intensité. Cancer Radiother 2006. [DOI: 10.1016/j.canrad.2006.09.094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
21
|
Noel G, Feuvret L, Dhermain F, Mammar H, Nauraye C, Boisserie G, Beaudre A, Gaboriaud G, Habrand J, Mazeron J. Proton Dose Escalation in Base of the Skull and Upper Cervical Spine Chordomas. Int J Radiat Oncol Biol Phys 2005. [DOI: 10.1016/j.ijrobp.2005.07.457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
22
|
Noël G, Feuvret L, Dhermain F, Mammar H, Haie-Méder C, Ponvert D, Hasboun D, Ferrand R, Nauraye C, Boisserie G, Beaudré A, Gaboriaud G, Mazal A, Touboul E, Habrand JL, Mazeron JJ. Les chordomes de la base du crâne et du rachis cervical haut. À propos d'une série de 100 patients irradiés selon une technique conformationnelle 3D par une association de faisceaux de photons et de protons. Cancer Radiother 2005; 9:161-74. [PMID: 15979920 DOI: 10.1016/j.canrad.2005.04.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2004] [Revised: 04/18/2005] [Accepted: 04/22/2005] [Indexed: 10/25/2022]
Abstract
OBJECTIVE To define prognostic factors for local control and survival in 100 consecutive patients treated by fractionated photon and proton radiation for chordoma of the skull base and upper cervical spine. PATIENTS AND METHODS Between December 1995 and August 2002, 100 patients (median age: 53 years, range: 8-85, M/F sex-ratio: 3/2), were treated by a combination of high-energy photons and protons. The proton component was delivered by the 201 MeV proton beam of the Centre de Protonthérapie d'Orsay (CPO). The median total dose delivered to the gross tumour volume was 67 Cobalt Gray Equivalent (CGE) (range: 60-71). A complete surgery, incomplete surgery or a biopsy was performed before the radiotherapy in 16, 75 and 9 cases, respectively. RESULTS With a median follow-up of 31 months (range: 1-87), 25 tumours failed locally. The 2 and 4-year local control rates were 86.3% (+/-3.9%) and 53.8% (+/-7.5%), respectively. According to multivariate analysis, less than 95% of the tumour volume encompassed by the 95% isodose line (P=0.048; RR: 3.4 IC95% [1.01-11.8]) and a minimal dose less than 56 CGE (p=0.042; RR: 2.3 IC95% [1.03-5.2]) were independent prognostic factors of local control. Ten patients died. The 2 and 5-year overall survival rates were 94.3% (+/-2.5%) and 80.5% (+/-7.2%). According to multivariate analysis, a controlled tumour (P=0.005; RR: 21 IC95% [2.2-200]) was the lonely independent favourable prognostic factor for overall survival. CONCLUSION In chordomas of the skull base and upper cervical spine treated by surgical resection followed by high-dose photon and proton irradiation, local control is mainly dependent on the quality of radiation, especially dose-uniformity within the gross tumour volume. Special attention must be paid to minimise underdosed areas due to the close proximity of critical structures and possibly escalate dose-constraints to tumour targets in future studies, in view of the low toxicity observed to date.
Collapse
Affiliation(s)
- G Noël
- Centre de protonthérapie d'Orsay, institut Curie, CPO bâtiment 101, campus universitaire, 91898 Orsay cedex, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Noël G, Feuvret L, Calugaru V, Dhermain F, Mammar H, Habrand J, Mazeron J. Protonthérapie dans les chordomes de la base du crâne et du rachis cervical haut. Résultats du centre de Protonthérapie d’Orsay. Neurochirurgie 2005. [DOI: 10.1016/s0028-3770(05)83431-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
24
|
Noël G, Mammar H, Ferrand R, Desblancs C, Nauraye C, Mazeron JJ. [ANOCEF MEETING December 8, 2001. Summary of the meeting]. Rev Neurol (Paris) 2002; 158:497-509. [PMID: 11984496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
Affiliation(s)
- G Noël
- Centre de protonthérapie d'Orsay, Orsay, France
| | | | | | | | | | | |
Collapse
|
25
|
Lumbroso L, Levy C, Plancher C, Frau E, D'hermies F, Schlienger P, Dendale R, Mammar H, Delacroix S, Nauraye C, Noel G, Ferrand R, Desblancs C, Mazal A, Validire P, Asselain B, Desjardins L. [Results of proton beam irradiation for treatment of choroidal melanoma]. J Fr Ophtalmol 2002; 25:290-7. [PMID: 11941255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
Abstract
PURPOSE To evaluate the results of proton beam irradiation of choroidal melanomas on a large series of patients. PATIENTS AND METHODS Retrospective analysis of a series of patients treated with proton beam irradiation between 1991 and December 1998. The data were analyzed to evaluate the local tumor control as well as the general progression and metastatic rate of the patients. Statistical analysis served to isolate risk factors for relapse or metastasis. RESULTS We treated 1062 patients during the study period, with a median follow-up of 38 months. Local control was obtained for 97.1% of the patients. Tumors anterior to the equator were at risk for relapse. The survival rate was 92% at 2 years and 78% at 5 years. 73.1% of the 1062 patients died from metastasis, 6.1% of living patients presented with metastatic disease. The risk factors for death were the initial diameter, the age of the patient, and large tumor volume at diagnosis. Metastasis were essentially hepatic (94.6%). Risk factors for metastasis were: a large tumor volume, a lesion anterior or straddling the equator and the age of the patient. Ocular complications may induce a visual loss of 0.1 and less in 47% of the patients, due to optic nerve head and macular ischemia. 6% of the patients required secondary enucleation due to local complications (neovascular glaucoma). CONCLUSION Proton beam irradiation of choroidal melanoma allows good tumor control and eye retention. The survival prognosis is associated with the initial volume of the tumor. The functional results may be improved and new therapeutics are needed to treat metastatic disease.
Collapse
Affiliation(s)
- L Lumbroso
- Service d'Ophtalmologie, Institut Curie, 26 rue d'Ulm, 75231, Paris Cedex 05
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Lumbroso L, Desjardins L, Levy C, Plancher C, Frau E, D'Hermies F, Schlienger P, Mammar H, Delacroix S, Nauraye C, Ferrand R, Desblancs C, Mazal A, Asselain B. Intraocular inflammation after proton beam irradiation for uveal melanoma. Br J Ophthalmol 2001; 85:1305-8. [PMID: 11673294 PMCID: PMC1723769 DOI: 10.1136/bjo.85.11.1305] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
AIM To describe the inflammatory reaction that can occur following proton beam irradiation of uveal melanomas based on a large series of patients and to try to determine the risk factors for this reaction. METHODS Data from a cohort of patients with uveal melanoma treated by proton beam irradiation between 1991 and 1994 were analysed. The presence of inflammation was recorded and evaluated. Kaplan-Meier estimates and statistical analysis of general and tumour related risk factors were performed. RESULTS 28% of patients treated during this period presented with ocular inflammation (median follow up 62 months). Risks factors were essentially tumour related and were correlated with larger lesions (height > 5 mm, diameter > 12 mm, volume > 0.4 cm(3)). Multivariate analysis identified initial tumour height and irradiation of a large volume of the eye as the two most important risk factors. Ocular inflammation usually consisted of mild anterior uveitis, resolving rapidly after topical steroids and cycloplegics. The incidence of inflammation after proton beam irradiation of melanomas seems higher than previously reported and is related to larger lesions. Evidence of inflammation associated with uveal melanoma has been described and seems to be associated with tumour necrosis (spontaneous or after irradiation). The appearance of transient inflammation during the follow up of these patients may be related to the release of inflammatory cytokines during tumour necrosis. CONCLUSION Inflammation following proton beam irradiation is not unusual. It is correlated with larger initial tumours and may be related to tumour necrosis.
Collapse
Affiliation(s)
- L Lumbroso
- Department of Ophthalmology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Noël G, Habrand JL, Mammar H, Pontvert D, Haie-Méder C, Hasboun D, Moisson P, Ferrand R, Beaudré A, Boisserie G, Gaboriaud G, Mazal A, Kérody K, Schlienger M, Mazeron JJ. Combination of photon and proton radiation therapy for chordomas and chondrosarcomas of the skull base: the Centre de Protonthérapie D'Orsay experience. Int J Radiat Oncol Biol Phys 2001; 51:392-8. [PMID: 11567813 DOI: 10.1016/s0360-3016(01)01634-0] [Citation(s) in RCA: 86] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
PURPOSE Prospective analysis of local tumor control, survival, and treatment complications in 44 consecutive patients treated with fractionated photon and proton radiation for a chordoma or chondrosarcoma of the skull base. METHODS AND MATERIALS Between December 1995 and December 1998, 45 patients with a median age of 55 years (14-85) were treated using a 201-MeV proton beam at the Centre de Protonthérapie d'Orsay, 34 for a chordoma and 11 for a chondrosarcoma. Irradiation combined high-energy photons and protons. Photons represented two-thirds of the total dose and protons one-third. The median total dose delivered within the gross tumor volume was 67 cobalt Gray equivalent (CGE) (range: 60-70). RESULTS With a mean follow-up of 30.5 months (range: 2-56), the 3-year local control rates for chordomas and chondrosarcomas were 83.1% and 90%, respectively, and 3-year overall survival rates were 91% and 90%, respectively. Eight patients (18%) failed locally (7 within the clinical tumor volume and 1 unknown). Four patients died of tumor and 2 others of intercurrent disease. In univariate analysis, young age at time of radiotherapy influenced local control positively (p < 0.03), but not in multivariate analysis. Only 2 patients presented Grade 3 or 4 complications. CONCLUSION In skull-base chordomas and chondrosarcomas, the combination of photons with a proton boost of one-third the total dose offers an excellent chance of cure at the price of an acceptable toxicity. These results should be confirmed with a longer follow-up.
Collapse
Affiliation(s)
- G Noël
- Centre de Protonthérapie d'Orsay, Orsay, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Noël G, Ferrand R, Mammar H, Mazeron JJ. [Protontherapy is not an obsolete technic]. Bull Cancer 2001; 88:708-9. [PMID: 11495825] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Affiliation(s)
- G Noël
- Centre de protonthérapie d'Orsay, BP 65, 91402 Orsay Cedex, France
| | | | | | | |
Collapse
|
29
|
Schlienger M, Mérienne L, Lefkopoulos D, Nataf F, Mammar H, Deniaud-Alexandre E. [Re-irradiation of cerebral arteriovenous malformations. Experience of the Sainte-Anne-Tenon Group]. Neurochirurgie 2001; 47:324-31. [PMID: 11404712] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
BACKGROUND AND PURPOSE Between 20 to 50% of cerebral arteriovenous malformations treated with radiosurgery (RS) fail to obliterate 2 to 5 years after irradiation. Patients are not protected against the risks leading to treatment. Two therapeutic options can be used to eradicate the persisting nidus: micro-surgery and a second irradiation. Our group has reirradiated 39 such patients. MATERIAL From 1989 to 2000, 39 patients have been reirradiated (14 females and 25 males; median age 31 years). There were more left lesions: 59% than right (35%) and 5% on midline. The most frequent locations were: temporal 12 cases; parietal 8 cases; frontal 7 cases; thalamus 7 cases. The predominant first symptoms were hemorrhage (68.5%) and seizure (15.8%). Prior RS, 21/39 patients had embolization (53.8%) and 3 surgery. Method. Treatment has been performed with the same system for the first and the second radiosurgery for 37 patients. Planification and dosimetry improved during that period. The level of dose was similar for the 2 RS. MRI has been used as a non invasive follow-up tool. RESULTS Only 28 patients were evaluable because 7/39 patients had the second radiosurgery in 1999 or in 2000 and data were lacking at the time of writing for 4 patients. Obliteration rate was 17/28 (60.7%). Nine patients bled between the two radiosurgery procedures. COMPLICATIONS 4 new regressive deficits occurred after the second radiosurgery. The rate of parenchymal changes were higher, after the second radiosurgery. Except one patient who died of a non-related affection 2 years after obliteration of his cerebral arteriovenous malformation, thus 38/39 patients were alive. CONCLUSION This series was small compared to the potential number of candidates suffering from failure of the first radiosurgery, but the results are promising.
Collapse
Affiliation(s)
- M Schlienger
- Service d'Oncologie-Radiothérapie, Hôpital Tenon, 4, rue de la Chine, 75020 Paris
| | | | | | | | | | | |
Collapse
|
30
|
Meyer A, Lévy C, Blondel J, D'hermies F, Frau E, Schlienger P, Mammar H, Delacroix S, Nauraye C, Desblancs C, Ferrand R, Mazal A, Asselain B, Plancher C, Habrand J, Desjardins L. [Optic neuropathy after proton-beam therapy for malignant choroidal melanoma]. J Fr Ophtalmol 2000; 23:543-53. [PMID: 10880919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
Proton-beam irradiation is a conservative therapy commonly used for the treatment of uveal malignant melanomas. Some adverse effects such as optic neuropathy can compromise the visual outcome. We were interested in determining the risk factors for radiation papillopathy. Since there is currently no effective therapy, this is an interesting way to improve prevention of optic neuropathy. Six hundred sixty-two eyes had more than 24 month follow-up after proton-beam irradiation for uveal melanoma. In five hundred twenty-two cases, the clinical examination of the optic nerve head by ophthalmoscopy was possible. One-hundred eleven optic discs were pathologic, whereas 411 remained disease-free. Retrospective study of these two groups allowed to quantify the risk factors for optic neuropathy. The irradiation of more than 2mm of optic nerve at 30 Grays-equivalents appeared to be the major risk factor for optic neuropathy. For a given irradiation dose, the observed pattern of clinical responses was heterogeneous. These results are discussed and compared to the previous published reports. Visual results and life prognosis are also discussed, considering the optic nerve head status. Proton-beam therapy can preserve the optic nerve when the tumor location allows to keep it away from the irradiation-field. Patients must be informed about the risk of optic neuropathy after proton-beam irradiation.
Collapse
Affiliation(s)
- A Meyer
- Service d'Ophtalmologie, Institut Curie, 26, rue d'Ulm, 75005 Paris
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Schlienger M, Atlan D, Lefkopoulos D, Merienne L, Touboul E, Missir O, Nataf F, Mammar H, Platoni K, Grandjean P, Foulquier JN, Huart J, Oppenheim C, Meder JF, Houdart E, Merland JJ. Linac radiosurgery for cerebral arteriovenous malformations: results in 169 patients. Int J Radiat Oncol Biol Phys 2000; 46:1135-42. [PMID: 10725623 DOI: 10.1016/s0360-3016(99)00523-4] [Citation(s) in RCA: 143] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
PURPOSE To present the SALT group results using Linac radiosurgery (RS) for AVM in 169 evaluable patients treated from January 1990 thru December 1993. METHODS AND MATERIALS Median age was 33 years (range 6-68 years). Irradiation was the only treatment in 55% patients. Other treatment modalities had been used prior to RS in 45%: one or more embolizations in 36%, surgery in 6%, and embolization and surgery in 3% patients. Nidus were supratentorial in 94% patients, infratentorial in 6% patients. Circular 15 MV x-ray minibeams (6-20 mm) were delivered in coronal arcs by a GE-CGR Saturne 43 Linac. Patient set-up included a Betti arm-chair, a Talairach frame. Prescribed peripheral dose was 25 Gy on the 60%-70% isodose (max dose 100%). Arteriographic results were reassessed in December 1997 at 48 to 96 months follow-up. RESULTS The overall obliteration rate (OR) was 64% (108/169). AVM volumes ranged from 280 to 19,920 mm(3), median 2460 mm(3). OR was 70% for AVM </= 4200 mm(3) 4200 mm(3) (p 25 mm (p = 0.04). OR was 71%, in the absence of embolization, vs. 54% for previously embolized nidus (p = 0.03). OR was 71% for monocentric RS vs. 54% for multi-isocenters (p 28 Gy vs. 55% for values </= 28 Gy (p 79% vs. 57% for lower values (p 17 Gy, vs. 59% for mLd </= 16 Gy (p 40%, vs. 54% for mLi </= 40% (p 85% vs. 60% for CR </= 84% (NS). For patients treated according to our protocol, i.e., 24-26 Gy on the 60%-70% isodoses, OR was higher (68%) than for other patients (47%) (p = 0.02). After multivariate analysis, absence of previous embolization and mono isocentric-irradiation were independent factors predicting obliteration. Complications were: recurrent hemorrhage, 4 patients (1 patient died); brain necrosis on MRI, 2 patients; subsequent epilepsy, 4 patients; other subsequent neurologic deficits, 3 patients. CONCLUSION Overall OR was 64% (48-96 months follow-up). After monovariate analysis higher ORs were associated with smaller volumes </= 4200 mm(3), smaller nidus size </= 25 mm, absence of prior embolization, monoisocentric RS, higher values for mean and minimum lesion doses and compliance to our protocol. Higher values for the peripheral dose and isodose tended to give better results. Multivariate analysis showed that the absence of prior embolization and monoisocentric irradiation were independent factors predicting successful irradiation.
Collapse
Affiliation(s)
- M Schlienger
- Radiotherapy Radiophysics, Tenon Hospital, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Habrand JL, Haie-Meder C, Rey A, Mammar H, Pontvert D, Gaboriaud G, Couanet D, Lenir C, Valinta D, Ferrand R, Boisserie G, Beaudré A, Kerody K, Mazal A, Dupouy N, Bonomi M, Mazeron JJ. [Radiotherapy using a combination of photons and protons for locally aggressive intracranial tumors. Preliminary results of protocol CPO 94-C1]. Cancer Radiother 1999; 3:480-8. [PMID: 10630161 DOI: 10.1016/s1278-3218(00)88255-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
PURPOSE From October 1993 through July 1998, 48 assessable adult patients with non-resectable aggressive intracranial tumors were treated by a combination of high dose photon + proton therapy at the Centre de Protonthérapie d'Orsay. PATIENTS AND METHODS Grade 1 and 4 gliomas were excluded. Patients benefited from a 3D dose calculation based on high-definition CT and MRI, a stereotactic positioning using implanted fiducial markers and a thermoplastic mask. Mean tumor dose ranged between 63 and 67 Gy delivered in five weekly sessions of 1.8 Gy in most patients, according to the histological types (doses in Co Gy Equivalent, with a mean proton-RBE of 1.1). RESULTS With a median 18-month follow-up (range: four-58 months), local control in tumors located in the envelopes and in the skull base was 97% (33/34), and in parenchymal tumors, 43% (6/14) only. Two patients (5%) presented with a clinically severe radiation-induced necrosis (temporal lobe and chiasm). CONCLUSION In our experience, high-dose radiation combining photons and protons is a safe and highly efficient procedure in selected malignancies of the skull base and envelopes.
Collapse
|
33
|
Habrand JL, Mammar H, Ferrand R, Pontvert D, Bondiau PY, Kalifa C, Zucker JM. Proton beam therapy (PT) in the management of CNS tumors in childhood. Strahlenther Onkol 1999; 175 Suppl 2:91-4. [PMID: 10394410 DOI: 10.1007/bf03038901] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
At the Centre de Protontherapie d'Orsay, nine children with intra-cranial malignancies were treated between July 1994 and January 1998. Immediate and late tolerances were excellent in all cases (follow-up 2 to 50 months). Two patients recurred locally (marginal failures), seven are alive and doing well. At Loma Linda, 28 children were treated between 1991 and 1994, 16 for a benign tumor of the brain and twelve for a malignant one. With a follow-up of seven to 49 months, three patients died (grade 2 to 4 gliomas), one is living with a persistent disease. Four children had treatment-related toxicity (one cataract, two hormonal failures and two seizures). The other children are doing well. At MGH Boston, 18 children with skull base-cervical spine chordomas have been reported. At five years, actuarial survival and disease-free survival have been 68 and 63%, respectively. Children with cervical sites had a worse prognosis (p = 0.008). Four children had radiation-related morbidity: two pituitary failures, one temporal lobe necrosis, one temporal muscle fibrosis. In this experience, such rare tumors seemed to behave in children like in adults.
Collapse
|
34
|
Habrand JL, Mammar H, Bonomi M, Mazeron JJ, Pontvert D, Haie-Meder C, Lenir C, Ferrand R, Rey A. Tolérance du système nerveux aux hautes doses d'irradiation délivrées par protonthérapie. Cancer Radiother 1998. [DOI: 10.1016/s1278-3218(98)80108-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
35
|
Touboul E, Al Halabi A, Buffat L, Merienne L, Huart J, Schlienger M, Lefkopoulos D, Mammar H, Missir O, Meder JF, Laurent A, Housset M. Single-fraction stereotactic radiotherapy: a dose-response analysis of arteriovenous malformation obliteration. Int J Radiat Oncol Biol Phys 1998; 41:855-61. [PMID: 9652849 DOI: 10.1016/s0360-3016(98)00115-1] [Citation(s) in RCA: 67] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
PURPOSE Stereotactic radiotherapy delivered in a high-dose single fraction is an effective technique to obliterate intracranial arteriovenous malformations (AVM). To attempt to analyze the relationships between dose, volume, and obliteration rates, we studied a group of patients treated using single-isocenter treatment plans. METHODS AND MATERIALS From May 1986 to December 1989, 100 consecutive patients with angiographically proven AVM had stereotactic radiotherapy delivered as a high-dose single fraction using a single-isocenter technique. Distribution according to Spetzler-Martin grade was as follows: 79 grade 1-3, three grade 4, 0 grade 5, and 18 grade 6. The target volume was spheroid in 74 cases, ellipsoid in 11, and large and irregular in 15. The targeted volume of the nidus was estimated using two-dimensional stereotactic angiographic data and, calculated as an ovoid-shaped lesion, was 1900 +/- 230 mm3 (median 968 mm3; range 62-11, 250 mm3). The mean minimum target dose (Dmin) was 19 +/- 0.6 Gy (median 20 Gy; range: 3-31.5). The mean volume within the isodose which corresponded to the minimum target dose was 2500 +/- 300 mm3 (median 1200 mm3; range 75-14 900 mm3). The mean maximum dose (Dmax) was 34.5 +/- 0.5 Gy (median 35 Gy; range 15-45). The mean angiographic follow-up was 42 +/- 2.3 months (median 37.5; range 7-117). RESULTS The absolute obliteration rate was 51%. The 5-year actuarial obliteration rate was 62.5 +/- 7%. After univariate analysis, AVM obliteration was influenced by previous surgery (p = 0.0007), Dmin by steps of 5 Gy (p = 0.005), targeted volume of the nidus (< or = 968 mm3 vs. >968 mm3; p = 0.015), and grade according to Spetzler-Martin (grade 1-3 vs. grade 4-6; p = 0.011). After multivariate analysis, the independent factors influencing AVM obliteration were the Dmin [relative risk (RR) 1.9; 95% confidence interval (CI) 1.4-2.5; p < 0.0001] and grade distribution according to Spetzler-Martin (RR 1.4; 95% CI 1.1-1.7; p = 0.010). Delayed complications were observed in eight patients. The 5-year actuarial rate of delayed complications was 7.4%. CONCLUSION After stereotactic radiotherapy delivered in a single high dose using a single-isocenter technique, the success rate for complete obliteration is independently correlated to Dmin but does not seem to be influenced by Dmax and the targeted volume of the nidus.
Collapse
Affiliation(s)
- E Touboul
- Department of Radiation Oncology, Tenon Hospital, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Mazal A, Schwartz L, Lacroix F, Mammar H, Delacroix S, Ferrand R, Nauraye C, Desjardins L, Schlienger P, D'Hermies F, Frau E, Habrand JL, Rosenwald JC. A preliminary comparative treatment planning study for radiotherapy of age-related maculopathy. Radiother Oncol 1998; 47:91-8. [PMID: 9632299 DOI: 10.1016/s0167-8140(97)00180-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
PURPOSE We present a comparative planning of different approaches for external radiotherapy in age-related maculopathies. MATERIALS AND METHODS Calculated dose distributions and dose-volume histograms for (a) bilateral irradiation with 6 MV photons, (b) a single lateral-oblique beam using either photons, electrons or protons and (c) an anterior circular proton beam. RESULTS For lateral photon or electron beams the dose to the lens is usually lower than 10% of the dose to the macula. The entrance doses for bilateral photon beams are about 50% which increase up to 100% at the orbital bone. About 5 mm of optic nerves are irradiated at the maximal dose while the optic chiasma is spared. A single photon beam gives 50% of the dose to the fellow eye. The electron beam spares the fellow eye but gives a rather inhomogeneous dose to the target volume. For a lateral proton beam, 4 mm of optic nerve receives 90% of the dose, the skin dose is at least 70% of the dose to the macula and the lens and the fellow eye are spared. An anterior proton beam gives 90% of the dose to 1 mm of optic nerve and the 50% isodose approaches the periphery of the lens. CONCLUSION Doses to the critical structures can be dramatically diminished for all the techniques by reducing the beam size, but only if very precise set-up techniques are used. Proton beams are an attractive solution, but the impact of such a choice on the use of proton facilities and on the national health system should be carefully evaluated, as well as the risk of radio-induced secondary neoplasias.
Collapse
Affiliation(s)
- A Mazal
- Centre de Protonthérapie d'Orsay, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Schlienger M, Lefkopoulos D, Mérienne L, Touboul E, Missir O, Nataf F, Atlan D, Mammar H, Platoni P, Grandjean P, Oppenheim C, Meder J, Houdart E, Merland J. Linac radiosurgery for cerebral arteriovenous malformations (AVM): Results in 173 patients. Int J Radiat Oncol Biol Phys 1998. [DOI: 10.1016/s0360-3016(98)80277-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
38
|
Mammar H, Schlienger P, Desjardins L, Frau E, d'Hermies F, Caudron C, Delacroix S, Habrand JL. P69 Protonthérapie des angiomes choroïdiens compliqués. Cancer Radiother 1997. [DOI: 10.1016/s1278-3218(97)89677-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
39
|
Mammar H, Pontvert D, Mazeron JJ, Cohen C, Le Nir S, Moisson P, Haie CH, Pica A, Gaboriaud G, Valinta D, Ferrand R, Delacroix S, Mazal A, Naurey C, Desblancs CA, Baudrey A, Boisserie G, Keraudy K, Habrand JL. P70 Protonthérapie des tumeurs du système nerveux central et de la base du crâne. Expérience préliminaire du centre d'Orsay. Cancer Radiother 1997. [DOI: 10.1016/s1278-3218(97)89678-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
40
|
Desjardins L, Levy C, d'Hermies F, Frau E, Schlienger P, Habrand JL, Mammar H, Schwartz L, Mazal A, Delacroix S, Nauraye C, Ferrand R, Asselain B. [Initial results of proton therapy in choroidal melanoma at the d'Orsey Center for Proton Therapy; the first 464 cases]. Cancer Radiother 1997; 1:222-6. [PMID: 9295876 DOI: 10.1016/s1278-3218(97)89768-5] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
PURPOSE Retrospective analysis of the treatment of choroidal melanoma with protontherapy at the Centre de protonthérapie d'Orsay, France. PATIENTS AND METHODS Between September 1991 and September 1995, 612 patients presenting with choroidal melanoma were treated by protontherapy in Orsay. Following initial management of the first 464 patients, results were analyzed, as were results after a 1-year follow-up for 305 patients, a 2-year follow-up for 169 patients, and a 3-year follow-up for 59 patients. RESULTS Univariate analysis showed that the actuarial local recurrence rate was 5%, the 3-year survival rate 88%, and the overall metastasic rate 5%. The initial tumor volume was the most significant predictive factor for visual results and metastases. Multivariate analysis revealed that visual results were significantly related to the initial tumor volume, initial retinal detachment, and total dose delivered to the optic nerve and macula. CONCLUSION Protontherapy of choroidal melanoma allows in most cases conservation of the eye without modification of survival. Visual results mainly depend on the site and size of the tumor.
Collapse
|
41
|
Touboul E, Buffat L, Lefranc JP, Blondon J, Deniaud E, Mammar H, Laugier A, Schlienger M. Possibility of conservative local treatment after combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer. Int J Radiat Oncol Biol Phys 1996; 34:1019-28. [PMID: 8600084 DOI: 10.1016/0360-3016(95)02207-4] [Citation(s) in RCA: 59] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
PURPOSE The aims of this prospective study were to evaluate the outcome and the possibility of breast conservation therapy for patients with locally advanced noninflammatory breast cancer after primary chemotherapy followed by external preoperative irradiation. METHODS AND MATERIALS Between April 1982 and June 1990, 97 patients with locally advanced nonmetastatic and noninflammatory breast cancer were treated. The median follow-up was 93 months from the beginning of treatment. The induction treatment consisted of four courses of chemotherapy (doxorubicin, vincristine, cyclophosphamide, 5-fluorouracil) followed by preoperative irradiation (45 Gy to the breast and nodal areas). A fifth course of chemotherapy was given after irradiation therapy. Three different loco-regional approaches were proposed, depending on the tumoral response. In 37 patients (38%) with residual tumor larger than 3 cm in diameter or located behind the nipple or with bifocal tumors, mastectomy and axillary dissection were performed. Sixty other patients (62%) benefited from conservative treatment: 33 patients (34%) achieved complete remission and no surgery was done but additional radiation boost was given to the initial tumor bed; 27 patients (28%) who had a residual mass less than or equal to 3 cm in diameter were treated by wide excision and axillary dissection followed by a boost to the excision site. After completion of local therapy, all patients received a sixth course of chemotherapy. A maintenance adjuvant chemotherapy regimen without anthracycline was prescribed (12 monthly cycles). RESULTS The 5-year actuarial loco-regional relapse rate was 16% after radiotherapy alone, 16% following wide excision and radiotherapy, and 5.4% following mastectomy. The 5-year loco-regional relapse rate was significantly higher after conservative local treatment (wide excision and radiotherapy, and radiotherapy alone) than after mastectomy (p= 0.04). After conservative local treatment, the 5-year breast conserving rate of patients with loco-regional disease-free status was 84%. For all patients included in this study, the 5-year breast-conserving rate of those who were loco-regional disease-free was 52%. In multivariate analysis, the possibility of breast conservative treatment was significantly related to the initial tumor size and age (more conservative treatment for tumor size < 6cm and age < 50 years). Five- and 10-year overall survival rates and disease-free survival rates were 80, 69, 73, and 61% respectively. Five- and 10-year overall survival rates were not influenced by the local treatment (conservative vs. nonconservative local treatment, p = 0.9). On the other hand, local failure significantly decreased the 5- and 10-year overall survival rates (p , 0.0001). In multivariate analysis, three factors had a significant impact on overall survival and disease-free survival: tumor response after induction chemotherapy, initial tumor size, and clinical stage. Arm lymphedema was noted in 12.5% (8 out of 64) of the patients treated with axillary dissection and in 3% (1 out of 33) without axillary dissection. Cosmetic results were satisfactory in 79% of patients after wide excision and radiotherapy and in 71% of patients treated by radiotherapy alone. CONCLUSIONS Induction chemotherapy followed by preoperative irradiation may permit the selection of some patients with locally advanced breast cancer for conservative treatment. However, the impact of this treatment modality on long-term survival remains to be established.
Collapse
Affiliation(s)
- E Touboul
- Service de Cancérologie-Radiothérapie, Hôpital Tenon, Paris, France
| | | | | | | | | | | | | | | |
Collapse
|
42
|
|
43
|
Habrand JL, Schlienger P, Schwartz L, Pontvert D, Lenir-Cohen-Solal C, Helfre S, Mammar H, Haie-Meder C, Ferrand R, Mazal A. Clinical applications of proton therapy. Bull Cancer Radiother 1996; 83 Suppl:207s-11s. [PMID: 8949781 DOI: 10.1016/0924-4212(96)84914-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Proton therapy offers considerable potential advantages in the management of poorly resectable, radio-resistent tumors close to critical anatomical structures. So far over 15,000 patients have been treated worldwide with two major indications: conservative management of ocular melanomas in which local control exceeds 95% at 5 years and curative irradiation of sarcomas at the base of the skull and cervical canal, with a survival rate between 84 and 94% at 5 years. The different protocols tested currently worldwide are discussed.
Collapse
|
44
|
Habrand JL, Desjardins L, Mammar H, Mazal A. [Protontherapy. Clinical features]. Bull Cancer Radiother 1996; 83:247-53. [PMID: 9081322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
|
45
|
Mazal A, Schwartz L, Lacroix F, Mammar H, Delacroix S, Ferrand R, Nauraye C, Desjardins L, Schlenger P, Dhermies D, Frau E, Habrand J, Rosenwald J. 430Radiotherapy of age-related maculopathy: a preliminary comparative treatment planning study. Radiother Oncol 1996. [DOI: 10.1016/s0167-8140(96)80439-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|